Details for Patent: 7,094,781
✉ Email this page to a colleague
Which drugs does patent 7,094,781 protect, and when does it expire?
Patent 7,094,781 protects OPSUMIT and is included in one NDA.
This patent has thirty-one patent family members in twenty-three countries.
Summary for Patent: 7,094,781
Title: | Sulfamides and their use as endothelin receptor antagonists |
Abstract: | The invention relates to novel sulfamides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists. |
Inventor(s): | Bolli; Martin (Allschwil, CH), Boss; Christoph (Allschwil, CH), Fischli; Walter (Allschwil, CH), Clozel; Martine (Saint-Louis, FR), Weller; Thomas (Binningen, CH) |
Assignee: | Actelion Pharmaceuticals Ltd. (CH) |
Application Number: | 10/433,041 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,094,781 |
Patent Claim Types: see list of patent claims | Compound; |
Recent additions to Drugs Protected by US Patent 7,094,781
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 7,094,781
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Actelion | OPSUMIT | macitentan | TABLET;ORAL | 204410-001 | Oct 18, 2013 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,094,781
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
PCT/EP00/12890 | Dec 18, 2000 |
PCT Information | |||
PCT Filed | December 04, 2001 | PCT Application Number: | PCT/EP01/14182 |
PCT Publication Date: | July 11, 2002 | PCT Publication Number: | WO02/053557 |
International Family Members for US Patent 7,094,781
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 035610 | ⤷ Try a Trial | |||
Austria | 323079 | ⤷ Try a Trial | |||
Australia | 2002227984 | ⤷ Try a Trial | |||
Brazil | 0116237 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |